Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

How can nanotechnology help the fight against breast cancer?

Avitabile E, Bedognetti D, Ciofani G, Bianco A, Delogu LG.

Nanoscale. 2018 Jul 5;10(25):11719-11731. doi: 10.1039/c8nr02796j. Review.

PMID:
29917035
2.

Immune oncology, immune responsiveness and the theory of everything.

Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J.

J Immunother Cancer. 2018 Jun 5;6(1):50. doi: 10.1186/s40425-018-0355-5.

3.

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.

Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J.

Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Review.

4.

The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L.

Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.

5.

A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader SBJ, Bedri S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller LD, Bedognetti D, Hendrickx W.

Version 2. F1000Res. 2017 Mar 20 [revised 2018 Jan 1];6:296. doi: 10.12688/f1000research.10960.2. eCollection 2017.

6.

Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.

Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W.

Int J Mol Sci. 2017 Oct 24;18(10). pii: E2229. doi: 10.3390/ijms18102229. Review.

7.

Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells.

Orecchioni M, Bedognetti D, Newman L, Fuoco C, Spada F, Hendrickx W, Marincola FM, Sgarrella F, Rodrigues AF, Ménard-Moyon C, Cesareni G, Kostarelos K, Bianco A, Delogu LG.

Nat Commun. 2017 Oct 24;8(1):1109. doi: 10.1038/s41467-017-01015-3.

8.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

9.

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Maccalli C, Giannarelli D, Chiarucci C, Cutaia O, Giacobini G, Hendrickx W, Amato G, Annesi D, Bedognetti D, Altomonte M, Danielli R, Calabrò L, Di Giacomo AM, Marincola FM, Parmiani G, Maio M.

Oncoimmunology. 2017 May 8;6(7):e1323618. doi: 10.1080/2162402X.2017.1323618. eCollection 2017.

10.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

11.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

12.

Conservation of immune gene signatures in solid tumors and prognostic implications.

Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD.

BMC Cancer. 2016 Nov 22;16(1):911.

13.

Checkpoint Inhibitors and Their Application in Breast Cancer.

Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B.

Breast Care (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review.

14.

Interferon-γ and Tumor Necrosis Factor-α Polarize Bone Marrow Stromal Cells Uniformly to a Th1 Phenotype.

Jin P, Zhao Y, Liu H, Chen J, Ren J, Jin J, Bedognetti D, Liu S, Wang E, Marincola F, Stroncek D.

Sci Rep. 2016 May 23;6:26345. doi: 10.1038/srep26345.

15.

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.

Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28.

16.

Harnessing the immune system for the treatment of melanoma: current status and future prospects.

Guennoun A, Sidahmed H, Maccalli C, Seliger B, Marincola FM, Bedognetti D.

Expert Rev Clin Immunol. 2016 Aug;12(8):879-93. doi: 10.1080/1744666X.2016.1176529. Epub 2016 May 3. Review.

PMID:
27070898
17.

Disentangling the relationship between tumor genetic programs and immune responsiveness.

Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. Review.

PMID:
26967649
18.

Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.

Cocca M, Bedognetti D, La Bianca M, Gasparini P, Girotto G.

J Transl Med. 2016 Jan 22;14:22. doi: 10.1186/s12967-016-0778-z.

19.

Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors.

Orecchioni M, Jasim DA, Pescatori M, Manetti R, Fozza C, Sgarrella F, Bedognetti D, Bianco A, Kostarelos K, Delogu LG.

Adv Healthc Mater. 2016 Jan 21;5(2):276-87. doi: 10.1002/adhm.201500606. Epub 2015 Dec 20.

PMID:
26687729
20.

Prognostic and predictive immune gene signatures in breast cancer.

Bedognetti D, Hendrickx W, Marincola FM, Miller LD.

Curr Opin Oncol. 2015 Nov;27(6):433-44. doi: 10.1097/CCO.0000000000000234. Review.

PMID:
26418235
21.

Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus.

Ascierto ML, Bozzano F, Bedognetti D, Marras F, Schechterly C, Matsuura K, Picciotto A, Marenco S, Zhao Y, DeGiorgi V, Sommariva M, Moretta L, Wang E, Alter HJ, Marincola FM, De Maria A.

J Transl Med. 2015 Mar 1;13:77. doi: 10.1186/s12967-015-0428-x.

22.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.

23.

Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome.

Bedognetti D, Wang E, Marincola FM.

Oncoimmunology. 2014 Apr 9;3:e28727. eCollection 2014. No abstract available.

24.

The perception of nanotechnology and nanomedicine: a worldwide social media study.

Sechi G, Bedognetti D, Sgarrella F, Van Eperen L, Marincola FM, Bianco A, Delogu LG.

Nanomedicine (Lond). 2014 Jul;9(10):1475-86. doi: 10.2217/nnm.14.78.

PMID:
25253496
25.

The immune-related role of BRAF in melanoma.

Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, Worschech A, Uccellini L, Ascierto PA, Stroncek D, Palmieri G, Chouchane L, Wang E, Marincola FM.

Mol Oncol. 2015 Jan;9(1):93-104. doi: 10.1016/j.molonc.2014.07.014. Epub 2014 Aug 6.

26.

Impact of carbon nanotubes and graphene on immune cells.

Orecchioni M, Bedognetti D, Sgarrella F, Marincola FM, Bianco A, Delogu LG.

J Transl Med. 2014 May 21;12:138. doi: 10.1186/1479-5876-12-138. Review.

27.

Direct T cell-tumour interaction triggers TH1 phenotype activation through the modification of the mesenchymal stromal cells transcriptional programme.

Jin P, Civini S, Zhao Y, De Giorgi V, Ren J, Sabatino M, Jin J, Wang H, Bedognetti D, Marincola F, Stroncek D.

Br J Cancer. 2014 Jun 10;110(12):2955-64. doi: 10.1038/bjc.2014.235. Epub 2014 May 8.

28.

Melanoma NOS1 expression promotes dysfunctional IFN signaling.

Liu Q, Tomei S, Ascierto ML, De Giorgi V, Bedognetti D, Dai C, Uccellini L, Spivey T, Pos Z, Thomas J, Reinboth J, Murtas D, Zhang Q, Chouchane L, Weiss GR, Slingluff CL Jr, Lee PP, Rosenberg SA, Alter H, Yao K, Wang E, Marincola FM.

J Clin Invest. 2014 May;124(5):2147-59. Epub 2014 Apr 1.

29.

Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.

Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D.

Expert Opin Biol Ther. 2014 May;14(5):663-86. doi: 10.1517/14712598.2014.890586. Epub 2014 Mar 13. Review.

PMID:
24625306
30.

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, Sommariva M, Sertoli MR, Simon R, Wang E, Rosenberg SA, Marincola FM.

Br J Cancer. 2013 Oct 29;109(9):2412-23. doi: 10.1038/bjc.2013.557. Epub 2013 Oct 15.

31.

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Galon J, Angell HK, Bedognetti D, Marincola FM.

Immunity. 2013 Jul 25;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008. Review.

32.

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.

Murtas D, Maric D, De Giorgi V, Reinboth J, Worschech A, Fetsch P, Filie A, Ascierto ML, Bedognetti D, Liu Q, Uccellini L, Chouchane L, Wang E, Marincola FM, Tomei S.

Br J Cancer. 2013 Jul 9;109(1):76-82. doi: 10.1038/bjc.2013.335. Epub 2013 Jun 27.

33.

Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients.

Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH.

J Transl Med. 2013 Jun 12;11:145. doi: 10.1186/1479-5876-11-145.

34.

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.

Nature. 2013 Jun 27;498(7455):506-10. doi: 10.1038/nature12199. Epub 2013 Jun 2.

35.

Prediction of response to anticancer immunotherapy using gene signatures.

Wang E, Bedognetti D, Marincola FM.

J Clin Oncol. 2013 Jul 1;31(19):2369-71. doi: 10.1200/JCO.2013.49.2157. Epub 2013 May 28. No abstract available.

PMID:
23715576
36.

Common pathways to tumor rejection.

Wang E, Bedognetti D, Tomei S, Marincola FM.

Ann N Y Acad Sci. 2013 May;1284:75-9. doi: 10.1111/nyas.12063.

PMID:
23651198
37.

Functionalized carbon nanotubes as immunomodulator systems.

Pescatori M, Bedognetti D, Venturelli E, Ménard-Moyon C, Bernardini C, Muresu E, Piana A, Maida G, Manetti R, Sgarrella F, Bianco A, Delogu LG.

Biomaterials. 2013 Jun;34(18):4395-403. doi: 10.1016/j.biomaterials.2013.02.052. Epub 2013 Mar 16.

PMID:
23507086
38.

Functionalized multiwalled carbon nanotubes as ultrasound contrast agents.

Delogu LG, Vidili G, Venturelli E, Ménard-Moyon C, Zoroddu MA, Pilo G, Nicolussi P, Ligios C, Bedognetti D, Sgarrella F, Manetti R, Bianco A.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16612-7. doi: 10.1073/pnas.1208312109. Epub 2012 Sep 24.

39.

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, Balleari E, Racchi O, Zoppoli G, Orsi A, Alicino C, Icardi G, Marincola FM, Zupo S, Ferrarini M, De Maria A.

Blood. 2012 Aug 30;120(9):1954-7. No abstract available.

40.

IRF5 gene polymorphisms in melanoma.

Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM.

J Transl Med. 2012 Aug 21;10:170. doi: 10.1186/1479-5876-10-170.

41.

Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population.

Tomei S, Adams S, Uccellini L, Bedognetti D, De Giorgi V, Erdenebileg N, Ascierto ML, Reinboth J, Liu Q, Bevilacqua G, Wang E, Mazzanti C, Marincola FM.

Med Oncol. 2012 Dec;29(5):3456-61. doi: 10.1007/s12032-012-0255-3. Epub 2012 May 22.

42.

The stable traits of melanoma genetics: an alternate approach to target discovery.

Spivey TL, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q, Tomei S, Ascierto ML, Uccellini L, Reinboth J, Chouchane L, Stroncek DF, Wang E, Marincola FM.

BMC Genomics. 2012 Apr 26;13:156. doi: 10.1186/1471-2164-13-156.

43.

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.

Ascierto ML, Worschech A, Yu Z, Adams S, Reinboth J, Chen NG, Pos Z, Roychoudhuri R, Di Pasquale G, Bedognetti D, Uccellini L, Rossano F, Ascierto PA, Stroncek DF, Restifo NP, Wang E, Szalay AA, Marincola FM.

BMC Cancer. 2011 Oct 19;11:451. doi: 10.1186/1471-2407-11-451.

44.

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.

Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D.

J Transl Med. 2011 Oct 12;9:174. doi: 10.1186/1479-5876-9-174.

45.

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.

Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, Fox BA, Gajewski TF, Marincola FM, Butterfield LH.

J Transl Med. 2011 Sep 19;9:155. doi: 10.1186/1479-5876-9-155.

46.

Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.

Bedognetti D, Sertoli MR, Pronzato P, Del Mastro L, Venturini M, Taveggia P, Zanardi E, Siffredi G, Pastorino S, Queirolo P, Gardin G, Wang E, Monzeglio C, Boccardo F, Bruzzi P.

J Natl Cancer Inst. 2011 Oct 19;103(20):1529-39. doi: 10.1093/jnci/djr351. Epub 2011 Sep 15.

47.

An immunologic portrait of cancer.

Ascierto ML, De Giorgi V, Liu Q, Bedognetti D, Spivey TL, Murtas D, Uccellini L, Ayotte BD, Stroncek DF, Chouchane L, Manjili MH, Wang E, Marincola FM.

J Transl Med. 2011 Aug 29;9:146. doi: 10.1186/1479-5876-9-146. Review.

48.

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment.

Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC.

BMC Med Genomics. 2011 May 11;4:38. doi: 10.1186/1755-8794-4-38.

49.

Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Zoppoli G, Bianchi F, Bruzzone A, Calvia A, Oneto C, Passalia C, Balleari E, Bedognetti D, Ponomareva E, Nazzari E, Castelletti L, Castellan L, Minuto F, Ghio R, Ferone D.

Pituitary. 2012 Jun;15(2):209-14. doi: 10.1007/s11102-011-0311-6. Review.

PMID:
21503687
50.

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A.

J Immunol. 2011 May 15;186(10):6044-55. doi: 10.4049/jimmunol.1004095. Epub 2011 Apr 15.

Supplemental Content

Loading ...
Support Center